Covaxin receives GMP certificate from Hungary: Bharat Biotech

This is the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories, says the tweet.

August 05, 2021 10:59 am | Updated 11:09 am IST - Hyderabad:

Bharat Biotech's COVID-19 vaccine called COVAXIN has received GMP compliance certificate from Hungary. File Photo.

Bharat Biotech's COVID-19 vaccine called COVAXIN has received GMP compliance certificate from Hungary. File Photo.

Bharat Biotech's COVID-19 vaccine Covaxin has received Good Manufacturing Practices (GMP) compliance certificate from Hungary, the vaccine maker said on Thursday in a tweet.

"Another milestone in our account as COVAXIN receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories," the tweet said.

The approval received is from the National Institute of Pharmacy and Nutrition, Hungary certifying the GMP for the manufacture of Covaxin, a note posted on Twitter said.

The certificate of GMP is now listed on the EUDRAGMDP database which is the collection of records of the European Community of manufacturing authorisations and certificates of good manufacturing practice, Bharat Biotech said.

Bharat Biotech intends to submit documentation for emergency use authorisation to several additional countries worldwide, the company said.

"With this approval Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at Global quality standards and moving forward in the ongoing fight against the COVID-19 pandemic," the note said.

The recognition compliments the firm's commitment of driving world class innovation and being a frontrunner in the research and development of vaccines, it added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.